Article: Dendreon Names Ernest Bognar General Manager of Hanover, NJ Manufacturing Facility.

Article: PROVENGE EXTENDS SURVIVAL IN PATIENTS WITH PROSTATE ...
Biotech Business;  December 1, 2005 ;     700+ words ... ... D9902A) of PROVENGE(R) (sipuleucel-T), the company's investigational ... D9901). The company recently announced ... to market PROVENGE based on discussions ... seen in the company's first Phase ... the men in the PROVENGE group were alive ...

Article: Dendreon's Provenge Extends Survival in Advanced Prostate ...
Business Wire;  January 12, 2004 ;     700+ words ... ... trial (D9901) of Provenge(R), the Company's investigational ... and less receiving Provenge had a significant survival ... received treatment with Provenge and will continue to ... study protocol. The Company expects to present ...

Article: Dendreon Announces Provenge Significantly Improves ...
PR Newswire;  February 17, 2005 ;     700+ words ... ... announced today that Provenge(R), the Company's investigational ... analysis of the Company's first randomized ... patients receiving Provenge had a 4.5 month ... information about the company and its programs ... the efficacy of Provenge to

Article: Dendreon Corporation Announces Provenge Prostate Cancer ...
Business Wire;  December 11, 2002 ;     700+ words ... ... Administration, the company will amend the protocol ... III trial (D9902) of Provenge to enroll only advanced ... 34.7 percent of Provenge patients versus 4 percent ... patients). Overall, Provenge was well tolerated by ... Corporation is a biotechnology company developing targeted ...

Article: Dendreon Announces Data on PROVENGE Potency and Long-Term ...
PR Newswire;  April 19, 2009 ;     700+ words ... ... presented today data from its PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE(R) (sipuleucel-T) induces long ... evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen ...

Article: Opinion split on Dendreon's Provenge after panel ...
Bioworld Financial Watch;  April 16, 2007 ;     700+ words ... ... Dendreon has major chips on Provenge against asymptomatic, metastatic ... Delivery Cassette technology. Provenge deploys a recombinant form ... At the start of 2006, the company let go about 15 percent of ... and marketing jobs ahead of Provenge's hoped-for clearance ...

Article: Dendreon's Phase 3 Trial of Provenge Confirms Immune ...
Business Wire;  June 2, 2003 ;     700+ words ... ... vaccine and lead product candidate, Provenge(R), confirms that the underlying ... prostate cancer. The results show that Provenge treatment induced a highly significant ... compared to placebo (p=0.0003), with Provenge treated patients demonstrating an eight ...